Breo Ellipta vs Fasenra
Side-by-side cost comparison based on Medicare Part D data
Breo Ellipta
Fluticasone/Vilanterol
Manufactured by GlaxoSmithKline
Fasenra
Benralizumab
Manufactured by AstraZeneca
Breo Ellipta costs 92% less per claim than Fasenra ($221.00 vs $2,836.00). A generic version of Breo Ellipta is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Breo Ellipta | Fasenra |
|---|---|---|
| Avg Cost Per Claim | $221.00 | $2,836.00 |
| Total Medicare Spending | $1.2B | $987.0M |
| Total Beneficiaries | 680,000 | 32,000 |
| Total Claims | 5,240,000 | 348,000 |
| Annual Cost/Patient | $1,700.00 | $30,844.00 |
| Year-over-Year Change | -4.3% | +18.6% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Nov 14, 2031 |
| Manufacturer | GlaxoSmithKline | AstraZeneca |
| Condition | Asthma/COPD | Asthma/COPD |
| Generic Name | Fluticasone/Vilanterol | Benralizumab |
Breo Ellipta vs Fasenra: What the Data Shows
Breo Ellipta (Fluticasone/Vilanterol) and Fasenra (Benralizumab) are both used to treat asthma/copd. Based on Medicare Part D data, Breo Ellipta costs $221.00 per claim, which is 92% less than Fasenra at $2,836.00 per claim.
Medicare spent $1.2B on Breo Ellipta and $987.0M on Fasenra. In terms of patient reach, Breo Ellipta serves more beneficiaries (680,000 vs 32,000).
Year-over-year spending changed -4.3% for Breo Ellipta and +18.6% for Fasenra. Fasenra saw significant spending growth, suggesting increased utilization or price increases.
Breo Ellipta has a generic available, while Fasenra remains brand-only until its patent expires Nov 14, 2031.
Frequently Asked Questions
Breo Ellipta is cheaper at $221.00 per claim, compared to $2,836.00 for Fasenra. That makes Breo Ellipta about 92% less expensive per claim based on Medicare Part D data.
Yes, both Breo Ellipta and Fasenra are used to treat asthma/copd. Your doctor can help determine which medication is more appropriate for your specific situation.
Breo Ellipta has a generic version (Fluticasone/Vilanterol) available, which is typically much cheaper. Fasenra is currently brand-only, with patent expiring Nov 14, 2031.
Medicare Part D spent $1.2B on Breo Ellipta covering 680,000 beneficiaries, and $987.0M on Fasenra covering 32,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.